ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks
Latest agreement expands access to the PHCS and MultiPlan Networks
While early detection has vastly improved survival rates for many types of cancer, pancreatic cancer is often diagnosed at an advanced metastatic stage when patients have a five-year survival rate as low as
The Avantect Pancreatic Cancer Test was designed for patients at high risk of pancreatic cancer, including those newly diagnosed with type 2 diabetes who are at least 50 years old, as well as those with a relevant family history and/or a genetic predisposition. It detects pancreatic cancer by profiling the epigenomic biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA and uses advanced AI algorithms to combine that data with other genomic information. This 5hmC-based approach provides a more comprehensive view of the active biological changes related to tumor development, allowing clinicians to identify cancer far earlier than with conventional methods.
“Participation in Claritev’s PHCS and MultiPlan Networks is another critical commercial milestone that will make it easier for health plan members accessing Claritev’s provider networks to use our innovative early cancer detection technology,” said Dave Mullarkey, CEO at ClearNote Health. “We look forward to working with Claritev to enable early detection of pancreatic cancer in high-risk patients so they can live longer, healthier lives.”
For more information on the Avantect cancer tests, please visit www.avantect.com.
About ClearNote Health
ClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company’s patented core Virtuoso™ epigenomics platform builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. Its highly sensitive, noninvasive Avantect® pancreatic and ovarian diagnostic tests are designed to identify cancers in high-risk patient populations far earlier than conventional approaches, when patients are most likely to benefit from treatment. ClearNote Health’s headquarters and CLIA-certified, CAP-accredited laboratory are located in
About Claritev
Claritev is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality to the
Claritev serves more than 700 healthcare payors, over 100,000 employers, 60 million consumers and 1.4 million contracted providers. For more information, visit www.claritev.com.
ClearNote Health, the ClearNote Health logo, and Avantect, are registered trademarks of ClearNote Health.
References
1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10-27. doi: 10.14740/wjon1166.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312355362/en/
Media Contact
Andrew Noble
415-722-2129
andrew@bioscribe.com
Source: ClearNote Health